Replimune Class Action Lawsuit: An Informative Investor Guide

• A notice in a class action like the Replimune Class Action Lawsuit refers to the formal communication sent to potential class members informing them about the lawsuit and their rights to participate in it.

• This notice is a crucial part of the class action process as it ensures that all individuals who may be affected by the outcome of the Replimune Class Action Lawsuit are aware of their rights and can choose whether to opt-in or opt-out of the class.

• The notice typically contains information about the nature of the Replimune Class Action Lawsuit, the claims being made, and the potential benefits or risks associated with participation. It also provides instructions on how to file a claim or request exclusion from the class.

• Overall, the notice serves to promote transparency and fairness in the class action process by ensuring that all affected individuals have an opportunity to exercise their legal rights.

Allegations in the Replimune Class Action Lawsuit

Replimune is a clinical-stage biotechnology company that focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.  According to the Replimune Class Action Lawsuit, Replimune’s lead product candidate is RP1 (vusolimogene oderparepvec).

On October 20, 2025, Replimune allegedly published a press release announcing that the U.S. Food and Drug Administration (“FDA”) had accepted the resubmission of the Biologics License Application (“BLA”) for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen.

The Replimune Class Action Lawsuit alleges that Replimune also claimed that “[d]uring the past few months, Replimune has been working to address agency feedback,” that “[a]dditional information, data and analyses were included in the resubmission which will be part of the BLA review,” and that “[t]he FDA indicated this resubmission is considered to be a complete response to the complete response letter received in July 2025.”

The Replimune Class Action Lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (

• In connection with the BLA, the study design concerns previously communicated by the FDA were not addressed;
• Replimune had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients);
• As a result, RPL-001-16 and RP1-104 both had deficiencies which were likely to cause the FDA to reject the BLA; and
• As a result of the foregoing, defendants’ positive statements about Replimune’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On April 10, 2026, the FDA allegedly published a Complete Response Letter rejecting Replimune’s BLA for RP1 in connection with nivolumab.  According to the Replimune Class Action Lawsuit, the FDA identified several deficiencies for each of the studies – RPL-001-16 (IGNYTE) and RP1-104 (IGNYTE-3) – submitted by Replimune and found that “the evidence as presented does not meet the evidentiary standards required for regulatory approval, and the results of the additional exploratory analyses of the RPL-001-16 data do not alter our initial conclusion that the RPL-001-16 trial is not an adequate and well-controlled clinical investigation that demonstrates substantial evidence of effectiveness.”

The FDA allegedly revealed that “[t]o support resubmission of the BLA on October 9, 2025, [Replimune] provided [objective response rate] data from an early unplanned analysis” from RP1-104 which included only 40 patients, 10% of the planned enrollment of 400 patients.

The Replimune Class Action Lawsuit further alleges that the FDA disclosed it had “clearly communicated” its “concerns with the study design in multiple FDA interactions throughout [Replimune’s] development program,” but that “the study design concerns previously communicated were not addressed, and the contribution of [RP1] to the observed response rate in RPL-001-16 could not be determined.”  On this news, Replimune’s share price fell more than 19% before trading was halted, according to the complaint.

Later that same day, after the market closed, Replimune allegedly issued a press release discussing the FDA’s response letter for the RP1 BLA.  The Replimune Class Action Lawsuit further alleges that in the press release, Replimune conceded that “a randomized controlled trial was preferred” by the FDA, but also claimed that the FDA communicated that “if the data was sufficiently compelling, a single arm trial could be acceptable for consideration under accelerated approval.”  On this news, Replimune’s share price dropped over 64%, according to the complaint.